Pharma Drug Pricing Deadline: What Companies Are Doing and What's Next

Pharma's Response to Drug Pricing Pressure

• 💊 Pharmaceutical companies are expected to submit plans today to the Trump administration regarding voluntary drug price reductions.
• 💬 So far, companies have made few concrete promises, stating they are in talks with the administration.
• 🌍 CEOs agree with President Trump that other countries should pay more for drugs, but implementing this is complex due to existing price controls in places like Europe.

Direct-to-Consumer (DTC) Initiatives

• 🚚 Some companies are exploring moves to bring drugs directly to patients at lower prices.
• 💡 Bristol Myers Squibb is making its psoriasis drug, Stelara, available at over 80% below list price.
• 🌐 The industry's main lobbying group will launch a new DTC website aggregating medicines from member companies at lower prices.

Challenges and Systemic Issues

• ❓ The effectiveness of DTC initiatives is questioned, as even with an 80% discount, a drug could still cost $16,000 annually out-of-pocket.
• 🏥 Companies often point to insurance and the need for system fixes, suggesting drugs should be covered with no co-pays.
• 🔄 These strategies allow companies to appear responsive without necessarily lowering their overall revenue.

Administration's Focus and Future Developments

• 🎯 The current administration is heavily focused on the Most Favored Nations policy.
• 📄 A proposed drug pricing pilot program has been sent to the White House for review, indicating more actions may be forthcoming.